Phase II trial of high-dose cisplatin in patients with malignant mesothelioma

D. M. Mintzer, D. Kelsen, D. Frimmer, R. Heelan, R. Gralla

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Twenty-five patients with advanced malignant mesothelioma were treated in a phase II trial with high-dose cisplatin (DDP). All patients had measurable or evaluable disease. Seven patients had received prior chemotherapy. DDP (120 mg/m2) with mannitol and prehydration was given every 4 weeks for two doses and then every 6 weeks. Of 24 patients evaluable for response, three had partial responses (3, 3+, and 9 months; response rate, 13%; 95% confidence limits, 4%-31%) and one had minor response. All responses occurred in previously untreated patients. High-dose DDP has modest activity in malignant mesothelioma.

Original languageEnglish (US)
Pages (from-to)711-712
Number of pages2
JournalCancer Treatment Reports
Issue number6
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II trial of high-dose cisplatin in patients with malignant mesothelioma'. Together they form a unique fingerprint.

Cite this